Oclacitinib vs ciclosporin for canine atopic dermatitis — LIKELY

In dogs with atopic dermatitis, does oclacitinib vs ciclosporin differ in speed and degree of pruritus and lesion control?

Shelf #272 · gate-verified and displayed under the developer's blinded-trial rule

LIKELY: Oclacitinib relieves itch faster than ciclosporin in canine atopic dermatitis, and the two drugs converge to similar pruritus control by about 8 weeks. In the single head-to-head trial — a blinded, randomized clinical trial in 226 client-owned dogs at eight sites, incorporating a noninferiority test at day 28 — owner-assessed pruritus scores fell significantly more on oclacitinib at every time point up to day 28 (percentage reductions from baseline across days 1–84 ranged from 25.6 to 61.0% on oclacitinib vs 6.5 to 61.5% on ciclosporin); on day 56, ciclosporin-treated dogs showed a similar decrease in pruritus to oclacitinib-treated dogs; and the day-14 CADESI-02 lesion-score reduction from baseline was significantly greater on oclacitinib (58.7% vs 43.0%). Adverse events attributed to gastrointestinal signs were reported three times as often in the ciclosporin group. Limits, stated plainly: this is one trial, it is single-blind by its record's MeSH indexing (Single-Blind Method), there is no placebo arm, and the abstract does not report the noninferiority margin or its result — so 'faster onset, then similar control' is what is carded here, not formal equivalence. Oclacitinib vs placebo is Shelf #270 and oclacitinib vs prednisolone is Shelf #271; those trials are cross-pointed, not re-carded on this shelf. Drafted Nov 10, 2026 (VetMed build, topic #272); all figures from abstracts fetched and verified at drafting.

Little 2015: oclacitinib cut pruritus significantly more than ciclosporin up to day 28, with similar control by day 56 (226 dogs)

Blinded, randomized clinical trial vs ciclosporin, incorporating a noninferiority test at day 28 (record's own title and abstract wording; MeSH indexes Single-Blind Method)

Who: Dogs: a total of 226 client-owned dogs with a history of atopic dermatitis, enrolled from eight sites in a blinded, randomized clinical trial — oral oclacitinib 0.4–0.6 mg/kg twice daily for 14 days, then once daily, or oral ciclosporin 3.2–6.6 mg/kg once daily, for 12 weeks. Owners assessed pruritus using an enhanced visual analog scale (VAS); veterinarians assessed dermatitis using the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-02.

Result: On days 1, 2, 7, 14, 28, 56 and 84, the percentage reduction from baseline for owner-assessed pruritus changed from 25.6 to 61.0% in the oclacitinib group compared with 6.5 to 61.5% in the ciclosporin group; differences were significant at all time points up to day 28 (these are percentage reductions in scores from baseline, not proportions of dogs). On day 56, ciclosporin-treated dogs showed a similar decrease in pruritus to oclacitinib-treated dogs. On day 14, the percentage reduction from baseline CADESI-02 was significantly greater in the oclacitinib group (58.7%) than in the ciclosporin group (43.0%). Three times as many adverse events attributed to gastrointestinal signs were reported in the ciclosporin group compared with the oclacitinib group. The record concludes oclacitinib had a faster onset of action and a lower frequency of gastrointestinal side effects compared with ciclosporin.

Watch out: Single-blind, not double-blind: the record's MeSH carries Single-Blind Method, and the publication types are Comparative Study / Randomized Controlled Trial. There is no placebo arm, so this trial cannot say how either drug compares with no treatment (that is Shelf #270). The trial incorporated a noninferiority test at day 28 by design, but the abstract does not state the margin or the test result — 'not the same as proven equivalent.' Pruritus is owner-assessed on a visual analog scale.

Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol. 2015;26(1):23-30, e7-8. PMID: 25496303. Registry ID: none in the record. MeSH: Animals · Cyclosporine · Dermatitis, Atopic · Dermatologic Agents · Dog Diseases · Dogs · Female · Male · Pruritus · Pyrimidines · Single-Blind Method · Sulfonamides · Treatment Outcome

Synthesis: one single-blind head-to-head — faster itch relief on oclacitinib, similar control by week 8, more gut signs on ciclosporin

Synthesis

Who: Synthesis of the card above: Little 2015 (blinded, randomized trial, 226 client-owned dogs with atopic dermatitis at eight sites, 12 weeks). This shelf rests on that one trial.

Result: The practical choice this trial informs is about speed and tolerability, not about which drug ultimately controls more: pruritus reductions separated significantly in oclacitinib's favour at every point up to day 28, lesion scores (CADESI-02) fell more on oclacitinib at day 14 (58.7% vs 43.0% reduction from baseline), pruritus control looked similar by day 56, and gastrointestinal adverse events attributed to treatment were reported three times as often on ciclosporin. A dog that needs relief this week and a dog starting a long-term ciclosporin plan are different decisions, and this single trial speaks mainly to the first weeks.

Watch out: Single-trial, single-masked shelf — hence LIKELY, not PROBABLE. The day-84 figures are the ends of the reported reduction ranges (61.0% oclacitinib vs 61.5% ciclosporin), not a reported significant difference, and no placebo comparison exists on this shelf by design: see Shelf #270 (vs placebo) and Shelf #271 (vs prednisolone).

Synthesis of Little PR et al. PMID: 25496303. Registry ID as on the individual card.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.